BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38687937)

  • 1. Outcomes, responses, and prognostic analyses of intrathecal combined treatment for leptomeningeal metastasis from lung adenocarcinoma.
    Huang S; Kang X; Wang C; Zhang W; Jiang J; Kang Z; Yang S; Chen J; Chen F; Li W
    J Cancer Res Ther; 2024 Apr; 20(2):658-664. PubMed ID: 38687937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
    Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
    Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
    Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
    Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
    Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
    Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
    Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
    Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
    Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
    Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
    Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
    Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
    Mitsuya K; Nakasu Y; Mizokami Y; Takahashi T; Nakamura Y; Ono A; Toda Y; Yamamoto N; Harada H; Nishimura T
    No Shinkei Geka; 2012 Jun; 40(6):503-9. PubMed ID: 22647509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
    Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
    ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
    Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
    Lee Y; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
    J Neurooncol; 2013 Oct; 115(1):95-101. PubMed ID: 23832498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
    Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
    Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.
    Morris PG; Reiner AS; Szenberg OR; Clarke JL; Panageas KS; Perez HR; Kris MG; Chan TA; DeAngelis LM; Omuro AM
    J Thorac Oncol; 2012 Feb; 7(2):382-5. PubMed ID: 22089116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
    Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
    Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
    Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
    J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
    Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
    Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.